busulfan has been researched along with Muscular Dystrophy, Duchenne in 2 studies
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To analyze a Duchenne muscular dystrophy(DMD) patient's muscular regeneration, dystrophin expression and locomotive variation before and after he underwent umbilical cord blood stem cell transplantation in order to assess the therapeutic effect." | 1.33 | [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation]. ( Chen, C; Chen, W; Fang, JP; Feng, HY; Feng, SW; Huang, K; Huang, SL; Li, Y; Li, Z; Liu, Y; Lu, XL; Wen, JM; Xi, J; Xiao, LL; Xie, YM; Xu, HG; Yao, XL; Ye, X; Zeng, Y; Zhang, C; Zhang, M; Zhang, WX; Zhou, DH, 2005) |
| "Currently, Duchenne muscular dystrophy (DMD) patients are treated with chronic immunosuppression for muscle precursor cell transplantation (MT)." | 1.33 | Induction of tolerance across fully mismatched barriers by a nonmyeloablative treatment excluding antibodies or irradiation use. ( Bouchentouf, M; Camirand, G; Mills, P; Pichavant, C; Rothstein, D; Stephan, L; Tagmouti, S; Tremblay, JP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, C | 1 |
| Feng, HY | 1 |
| Huang, SL | 1 |
| Fang, JP | 1 |
| Xiao, LL | 1 |
| Yao, XL | 1 |
| Chen, C | 1 |
| Ye, X | 1 |
| Zeng, Y | 1 |
| Lu, XL | 1 |
| Wen, JM | 1 |
| Zhang, WX | 1 |
| Li, Z | 1 |
| Feng, SW | 1 |
| Xu, HG | 1 |
| Huang, K | 1 |
| Zhou, DH | 1 |
| Chen, W | 1 |
| Xie, YM | 1 |
| Xi, J | 1 |
| Zhang, M | 1 |
| Li, Y | 1 |
| Liu, Y | 1 |
| Stephan, L | 1 |
| Pichavant, C | 1 |
| Bouchentouf, M | 1 |
| Mills, P | 1 |
| Camirand, G | 1 |
| Tagmouti, S | 1 |
| Rothstein, D | 1 |
| Tremblay, JP | 1 |
2 other studies available for busulfan and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
[Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
Topics: Alprostadil; Busulfan; Child; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclo | 2005 |
Induction of tolerance across fully mismatched barriers by a nonmyeloablative treatment excluding antibodies or irradiation use.
Topics: Animals; Animals, Newborn; Busulfan; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; | 2006 |